"Tentatively Positive" into Eliem's (ELYM) ETX-810 Data - Stifel Reiterates Stock at Buy
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating on Eliem Therapeutics Inc. (NASDAQ: ELYM) ahead of the upcoming ETX-810 readout ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
